T. Rowe Price Associates
ANTX icon

T. Rowe Price Associates’s AN2 Therapeutics ANTX Stock Holding History

T. Rowe Price Associates’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Buy
+22,022
New +$94.7K ﹤0.01% 3133
2024
Q1 		– Sell
-187,399
Closed -$3.84M – 2958
2023
Q4 		$3.84M Buy
+187,399
New +$3.14M ﹤0.01% 1289

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

T. Rowe Price Associates's ANTX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 22,022 shares worth $107K. The stake represents ﹤0.01% of the portfolio and ranks #3133 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in ANTX as recently as Q4 2023.

T. Rowe Price Associates first reported a position in ANTX in Q4 2023 and has held it in 2 quarters since. The position peaked at $3.84M in Q4 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • T. Rowe Price Associates held 22,022 shares of AN2 Therapeutics worth $107K as of Q2 2026.
  • AN2 Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3133 holding.
  • T. Rowe Price Associates first reported a position in AN2 Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • T. Rowe Price Associates's AN2 Therapeutics position peaked at $3.84M in Q4 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.